

Differential activation and modulation of the glucagon-like peptide-1 receptor by small molecule ligands

Denise Wootten, Emilia E Savage, Francis A Willard, Ana B Bueno, Kyle W Sloop, Arthur Christopoulos, Patrick M Sexton

Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences and Department of Pharmacology, Monash University, Parkville, Victoria 3052, Australia (DW, EES, AC, PMS), Endocrine Discovery (KWS) and Translational Science and Technologies (FSW), Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA, Centro de Investigación Lilly (ABB), Eli Lilly and Company, Alcobendas, Spain

Running Title: Differential modulation of the GLP-1R

Address correspondence to: Prof. Patrick M. Sexton, Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia.

Phone: (03) 9903 9069

Fax: (03) 9903 9581

Email: patrick.sexton@monash.edu

Text pages: 24

Number of tables: 4

Number of figures: 9

Number of references: 29

Number of words in Abstract: 241

Number of words in Introduction: 749

Number of words in Discussion: 1465

Abbreviations: β -Arr, beta arrestin; BETP, 4-(3-benzyloxyphenyl)-2-ethylsulfinyl-6-(trifluoromethyl)pyrimidine; Boc5, 1,3-bis [[4-(tert-butoxy-carbonylamino)benzoyl]amino]-2,4-bis[3-methoxy-4-(thiophene-2-carbonyloxy)-phenyl]cyclobutane-1,3-dicarboxylic acid; BSA, bovine serum albumin; CHO, Chinese hamster ovary; Compound 2, 6,7-dichloro-2-methylsulfonyl-3-tert-butylaminoquinoxaline; DMEM, Dulbecco's modified Eagle's medium; ERK1/2, extracellular signal-related kinases 1 and 2; FBS, fetal bovine serum; GLP-1, glucagon-like peptide; GLP-1R, glucagon-like peptide-1 receptor; GPCR, G protein-coupled receptor; iCa^{2+} , intracellular calcium; TT15, (2S-3-(4'-cyanobiphenyl-4-yl)-2-({[(8S)-3-{4-[(3,4-dichlorobenzyl)oxy]phenyl}-2-oxo-7-(phenylcarbonyl)-2,3,6,7,8,9-nexahydro-1H-[1,4]oxazino[3,2-G]isoquinolin-8-yl]carbonyl}amino)propanoic acid.

Abstract

The glucagon-like peptide-1 receptor (GLP-1R) is a major therapeutic target for the treatment of type 2 diabetes due to its role in glucose homeostasis. Despite the availability of peptide based GLP-1R drugs for treatment of this disease, there is great interest in developing small molecules that can be administered orally. The GLP-1R system is complex, with multiple endogenous and clinically used peptide ligands that exhibit different signalling biases at this receptor. This study revealed that small molecule ligands acting at this receptor are differentially biased to peptide ligands and also from each other with respect to the signalling pathways that they activate. Furthermore, allosteric, small molecule ligands were also able to induce bias in signalling mediated by orthosteric ligands. This was dependent on both the orthosteric and allosteric ligand as no two allosteric-orthosteric ligand pairs could induce the same signalling profile. We highlight the need to profile compounds across multiple signalling pathways and in combination with multiple orthosteric ligands in systems such as the GLP-1R where more than one endogenous ligand exists. In the context of pleiotropical coupling of receptors and the interplay of multiple pathways leading to physiological responses, profiling of small molecules in this manner may lead to a better understanding of the physiological consequences of biased signalling at this receptor. This could enable the design and development of improved therapeutics that have the ability to fine-tune receptor signalling leading to beneficial therapeutic outcomes while reducing side effect profiles.

Introduction

Type 2 diabetes mellitus (DM) and its associated obesity are predominantly characterised by a decrease in peripheral tissue response to insulin in association with impaired pancreatic β -cell function that results in an increase in fasting glycemia (DeFronzo, 1992). The incretin hormone, glucagon-like peptide-1 (GLP-1) has well-established effects on pancreatic β -cell insulin secretion and, despite a reduction in secreted levels of this hormone in diabetic patients, it retains its potent insulinotropic activity. This action, combined with a number of other important effects, including reduction in glucagon secretion, delayed gastric emptying, induction of satiety and increasing pancreatic β -cell mass, have attracted significant interest in GLP-1 and related analogues for the treatment of type 2 DM (Drucker and Nauck, 2006).

GLP-1 exerts its effects by binding to the GLP-1 receptor (GLP-1R), which belongs to the family B subclass of the G protein-coupled receptor (GPCR) superfamily. In recent years, it has become clear that individual GPCRs can exist in multiple receptor conformations and can elicit numerous functional responses, both G protein and non-G protein-mediated. This has led to the discovery that different ligands can stabilise distinct subsets of receptor conformations that can 'traffic' stimulus to diverse functional outputs with varying prominence, a concept referred to as biased agonism (also known as functional selectivity, stimulus bias or ligand-directed signalling) (Kenakin, 2011). The GLP-1R is predominantly expressed in pancreatic β -cells and mediates its effects through coupling primarily to $G\alpha_s$, resulting in an increase in cAMP, cell depolarisation and an increase in cytosolic calcium that ultimately promotes insulin secretion (Drucker et al., 1987; Holz et al., 1993). Although cAMP formation is a critical component of GLP-1R-mediated signalling required for insulin secretion, there are also roles of other signalling pathways in augmentation of insulin responses. In addition to cAMP formation, activated GLP-1Rs can promote epidermal growth factor receptor transactivation (Buteau et al., 2003), phosphatidylinositol 3 kinase activity, insulin receptor substrate-2 signaling (Park et al., 2006), extracellular signal-regulated kinase 1 and 2 (ERK1/2) activity (Montrose-Rafizadeh et al., 1999), mobilisation of intracellular calcium (iCa^{2+}) (Baggio and Drucker, 2007), as well as nuclear translocation of PKC to mediate β -cell proliferation and differentiation and promote insulin gene transcription (Buteau et al., 2003). Recent studies also support an essential role of β -arrestins in downstream GLP-1R-mediated insulin secretion (Quoyer et al., 2010; Sonoda et al., 2008). Although some of these pathways have been linked to therapeutically relevant outputs, such

as insulin secretion and β -cells survival, the underlying GLP-1R-mediated signaling required for therapeutically beneficial effects, such as delaying gastric emptying and inducing satiety, are not fully understood.

Currently, approved therapeutics acting at the GLP-1R are peptide-based, however there is substantial interest in development of small molecule drugs. In recent years, there have been an increasing number of reports showing discovery of structurally diverse small molecule agonists of the GLP-1R (Willard et al., 2012a). These include (but are not limited to) a series of quinoxalines, the best characterised being Compound 2, a series of pyrimidines, the best characterised being BETP, substituted cyclobutanes such as Boc5, and a series of compounds reported in patents by Transtech Pharma. In addition to displaying agonism in their own right, small molecule compounds that bind allosterically to the GLP-1R have the potential to modulate the function of endogenous hormones, allowing fine control of receptor function and/or spatial and temporal elements of endogenous orthosteric peptide signalling. There are many orthosteric peptide agonists of the GLP-1R including multiple endogenous ligands, as well as several peptides that are used therapeutically or are in clinical trials (Baggio and Drucker, 2007). All peptide agonists studied to date preferentially activate cAMP over ERK1/2 and iCa^{2+} mobilisation *in vitro* (Koole et al., 2010). However, the relative degree of bias is variable between ligands, with truncated GLP-1 peptides and exendin-4 having greater bias toward cAMP than full length GLP-1 peptides and oxyntomodulin (Koole et al., 2010). In addition, allosteric ligands can differentially alter the signaling profile mediated by these endogenous peptides and can therefore induce biased signaling in a peptide-specific manner.

While most of the small molecules developed to date are not drug-like compounds, they may represent pharmacophores that can be further optimised for clinical evaluation. They also provide us with a range of useful research tools that can be utilised to help understand the mechanism by which these small molecules bind and exert their physiological effects. In this study, we used an analytical approach, investigating the signalling of the GLP-1R across multiple signalling pathways to assess and quantify stimulus bias for a range of low molecular weight ligands (both peptide and non-peptide). The ability of these small ligands to act allosterically to modulate the responses and bias of distinct orthosteric peptide ligands was also assessed.

Materials and Methods

Materials Small molecule GLP-1 ligands 4-(3-benzyloxyphenyl)-2-ethylsulfinyl-6-(trifluoromethyl)pyrimidine (BETP) (Sloop et al., 2010), 6,7-dichloro-2-methylsulfonyl-3-tert-butylaminoquinoxaline (Compound 2) (Knudsen et al., 2007), 1,3-bis [[4-(tert-butoxycarbonylamino)benzoyl]amino]-2,4-bis[3-methoxy-4-(thiophene-2-carbonyloxy)-phenyl]cyclobutane-1,3-dicarboxylic acid (Boc5) (Chen et al., 2007), (2S-3-(4'-cyanobiphenyl-4-yl)-2-({[(8S)-3-{4-[(3,4-dichlorobenzyl)oxy]phenyl}-2-oxo-7-(phenylcarbonyl)-2,3,6,7,8,9-nexahydro-1H-[1,4]oxazino[3,2-G]isoquinolin-8-yl]carbonyl}amino)propanoic acid (TT15) (Rao, 2009) and BMS21 (Mapelli et al., 2009) were synthesized according to literature and standard methods (see supplemental information for more details). GLP-1(7-36)NH₂, GLP-1(1-36)NH₂, exendin-4 and oxyntomodulin were purchased from American peptides (Sunnyvale, CA, USA). Dulbecco's Modified Eagle's Medium (DMEM) and Fluo-4 AM were purchased from Invitrogen (Carlsbad, CA, USA). Foetal bovine serum (FBS) was purchased from Thermo Electron Corporation (Melbourne, VIC, Australia). AlphaScreen reagents, 96 well UniFilter GF/C filter plates, 384-well Proxiplates and Microscint 40 scintillant were purchased from PerkinElmer Life and Analytical Sciences (Waltham, MA, USA). SureFire™ ERK1/2 reagents were obtained from TGR Biosciences (Adelaide, SA, Australia). All other reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA) or BDH Merck (Melbourne, Victoria, Australia) and were of an analytical grade.

Transfections and Cell Culture. Human GLP-1Rs were isogenically integrated into FlpIn-Chinese hamster ovary (FlpInCHO) cells (Invitrogen) and selection of receptor-expressing cells accomplished by treatment with 600 µg ml⁻¹ hygromycin-B as previously described (May et al., 2007). Transfected and parental FlpInCHO cells were maintained in DMEM supplemented with 10% heat-inactivated FBS and incubated in a humidified environment at 37°C in 5% CO₂.

Radioligand Binding Assay. FlpInCHO GLP-1R cells were seeded at a density of 3 x 10⁴ cells/well into 96-well culture plates and incubated overnight at 37°C in 5% CO₂, and radioligand binding carried out as previously described (Koole et al., 2011). For each cell line in all experiments, total binding was defined by 0.5 nM ¹²⁵I-exendin(9-39) alone, and nonspecific binding was defined by 1 µM exendin(9-39). For analysis, data are normalised to the specific binding for each individual experiment.

cAMP Accumulation Assay. FlpInCHO WT and mutant human GLP-1R cells were seeded at a density of 3×10^4 cells/well into 96-well culture plates and incubated overnight at 37°C in 5% CO₂, and cAMP detection carried out using the PerkinElmer AlphaScreen™ kit as previously described (Koole et al., 2010). All values were converted to concentration of cAMP using a cAMP standard curve performed in parallel, and data were subsequently normalized to the response of 100 μM forskolin.

pERK1/2 Assay. FlpInCHO GLP-1R cells were seeded at a density of 3×10^4 cells/well into 96-well culture plates and incubated overnight at 37°C in 5% CO₂. Receptor-mediated pERK1/2 was determined using the AlphaScreen™ ERK1/2 SureFire™ protocol as previously described (May et al., 2007). Initial pERK1/2 time course experiments were performed over 1 h to determine the time at which agonist-mediated pERK1/2 was maximal. Subsequent experiments were then performed at the time required to generate a maximal pERK1/2 response (7 min). Data were normalized to the maximal response elicited by 10% FBS determined at 6 min (peak FBS response).

Intracellular Ca²⁺ Mobilisation Assay. FlpInCHO GLP-1R cells were seeded at a density of 3×10^4 cells/well into 96-well culture plates and incubated overnight at 37°C in 5% CO₂, and receptor-mediated intracellular Ca²⁺ mobilisation determined as previously described (Werry et al., 2005). Fluorescence was determined immediately after ligand addition, with an excitation wavelength set to 485 nm and an emission wavelength set to 520 nm, and readings taken every 1.36 s for 120 s. Peak magnitude was calculated using five-point smoothing, followed by correction against basal fluorescence. The peak value was used to create concentration-response curves. Data were normalized to the maximal response elicited by 100 μM ATP.

β-Arrestin Recruitment Assays. FlpIn CHO cell lines stably expressing GLP-1 receptor-Rluc8 and either β-arrestin1- or β-arrestin2-Venus were generated using gateway technology as previously described (Willard et al., 2012b). Cells were seeded in 96-well white culture plates at a density of 40,000 cells/well and cultured for 24 h. Cells were rinsed once with HBSS to remove traces of phenol red and incubated in fresh HBSS for a further 15 min. The Rluc substrate coelenterazine-h was added to reach a final concentration of 5 μM. After a 5 min incubation, the corresponding agonist was added and bioluminescence resonance energy transfer (BRET) readings were collected using a LumiSTAR Omega instrument that allows sequential integration of signals detected in the 465-505 and 515-555 nm windows using

filters with the appropriate band pass. The BRET signal was calculated by subtracting the ratio of 515-555 nm emission over 465-505 nm emission for a vehicle treated cell sample from the same ratio for the ligand treated cell sample. In this calculation, the vehicle treated cell sample represents background and results are expressed as ligand-induced BRET. This eliminates the requirement for measuring a donor only control sample. Initial time course experiments were performed over 20 min to determine the time at which β -arrestin1 and β -arrestin2 recruitment was maximal for each ligand in the absence and presence of BETP. Co-addition of ligands was performed for interaction assays and BRET signals were collected at this peak time point.

Data Analysis. Data were analysed using Prism 5.03 (GraphPad, La Jolla, CA, USA) using the three parameter logistic equation or an operation model of allosteric agonism.

Allosteric modulator inhibition binding data were fitted to the following allosteric ternary complex model. In this case, non depletion of ligands was assumed (Avlani et al., 2008):

$$Y = \frac{B_{max} \times [A]}{[A] + K_{App}} + NS \quad (1)$$

where

$$K_{App} = \frac{K_A \times K_B}{\alpha \times [B] + K_B} \times \frac{1 + [I]/K_I + [B]/K_B + (\alpha' \times [I] \times [B])}{K_I \times K_B} \quad (2)$$

where Y represents radioligand binding, B_{max} denotes maximal binding site density, and NS denotes the fraction of non-specific binding. [A] and K_A denote the concentration of radioligand and equilibrium dissociation constant for the radioligand, respectively. [B] and K_B denote the concentration of allosteric ligand and equilibrium dissociation constant for the allosteric ligand, respectively. [I] and K_I denote the concentration of peptide agonist used in competition with the radioligand and the equilibrium dissociation constant for the peptide agonist, respectively. α and α' represent cooperativity factors, which are defined as the allosteric interaction of the modulator with the radioligand, and modulator with the peptide agonist, respectively. Values of α or $\alpha' > 1$ are indicative of an allosteric-mediated increase in

binding activity, while values of $0 < \alpha$ or $\alpha' < 1$ are indicative of an allosteric-mediated decrease in binding affinity.

To compare agonist profiles and quantify stimulus bias (functional selectivity) between the different ligands, agonist concentration-response curves were fitted to the following form of the operational model of agonism ((Black and Leff, 1983; Evans et al., 2011; Koole et al., 2010),

$$Y = basal + \frac{(E_m - basal) \left(\frac{\tau}{K_A}\right)^n [A]^n}{[A]^n \left(\frac{\tau}{K_A}\right)^n + \left(1 + \frac{[A]}{K_A}\right)^n} \quad (3)$$

where E_m is the maximal possible response of the system; *basal* is the basal level of response; K_A denotes the equilibrium dissociation constant of the agonist (A); τ is an index of the signaling efficacy of the agonist and is defined as R_T/K_E , where R_T is the total number of receptors and K_E is the coupling efficiency of each agonist-occupied receptor; and n is the slope of the transducer function that links occupancy to response. The analysis assumes that the maximal system responsiveness (E_m) and the transduction machinery utilized for a given cellular pathway are the same for all agonists, such that the E_m and transducer slope (n) are shared between agonists. The ratio, τ/K_A (determined as a logarithm *i.e.* $\log(\tau/K_A)$) is referred to herein as the “transduction coefficient” (Kenakin et al., 2012), as this composite parameter is sufficient to describe agonism and bias for a given pathway, *i.e.* stimulus-biased agonism can result from either a selective affinity (K_A^{-1}) of an agonist for a given receptor state(s) and/or a differential coupling efficacy (τ) toward certain pathways. To cancel the impact of cell-dependent effects on the observed agonism at each pathway, the $\log(\tau/K_A)$ values were then normalized to that determined for the endogenous agonist, GLP-1(7-36)NH₂, at each pathway to yield a “normalized transduction coefficient,” $\Delta\log(\tau/K_A)$, *i.e.* $\Delta\log(\tau/K_A) = \log(\tau/K_A)_{\text{test}} - \log(\tau/K_A)_{\text{GLP-1(7-36)NH}_2}$. Finally, to determine the actual bias of each agonist for different signaling pathways, the $\Delta\log(\tau/K_A)$ values were evaluated statistically between the pathways. The ligand bias of an agonist for one pathway, j_1 , over another, j_2 , is given as

$$Bias = 10^{\Delta\log(\frac{\tau}{K_A})_{j_1-j_2}} \quad (4)$$

where

$$\Delta\Delta\text{Log}\left(\frac{\tau}{K_A}\right)_{j1-j2} = \log(\text{bias}) = \Delta\text{log}\left(\frac{\tau}{K_A}\right)_{j1} - \Delta\text{log}\left(\frac{\tau}{K_A}\right)_{j2} \quad (5)$$

A lack of functional selectivity will thus result in bias values not substantially different from 1 between pathways and, hence, log(bias) values not significantly different from zero. To account for the propagation of error associated with the determination of composite parameters, the following equation was used.

$$\text{Pooled SE} = \sqrt{(\text{SE}_1)^2 + (\text{SE}_2)^2} \quad (6)$$

In cell signaling ligand interaction studies, data were fitted to the following two forms of an operational model of allosterism and agonism to derive functional estimates of modulator affinity and cooperativity (Aurelio et al., 2009; Leach et al., 2007)

$$E = \frac{E_m \left(\tau_A [A] (K_B + \alpha\beta[B]) + \tau_B [B] EC_{50} \right)^n}{EC_{50}^n (K_B + [B])^n + \left(\tau_A [A] (K_B + \alpha\beta[B]) + \tau_B [B] EC_{50} \right)^n} \quad (7)$$

$$E = \frac{E_m \left(\tau_A [A] (K_B + \alpha\beta[B]) + \tau_B [B] K_A \right)^n}{([A]K_B + K_A K_B + [B]K_A + \alpha[A][B])^n + \left(\tau_A [A] (K_B + \alpha\beta[B]) + \tau_B [B] K_A \right)^n} \quad (8)$$

where E_m is the maximum attainable system response for the pathway under investigation, [A] and [B] are the concentrations of orthosteric agonist and allosteric modulator/agonist, respectively, K_B is the dissociation constant of the allosteric modulator, EC_{50} is the concentration of orthosteric (full) agonist yielding 50% of the response between minimal and maximal receptor activation in the absence of allosteric ligand, n is a transducer slope factor linking occupancy to response, α is the binding cooperativity factor, β is an empirical scaling factor describing the allosteric effect of the modulator on orthosteric agonist signaling efficacy, respectively, and τ_A and τ_B are operational measures of the ligands' respective signaling efficacies that incorporate receptor expression levels and efficiency of stimulus-response coupling. Equation 4 was used in interaction studies performed between allosteirc

ligand (BEPT) and a full agonist agonist (in cAMP and pERK1/2 assays), while equation 5 was used when the BEPT was interacted with a partial agonist (in iCa^{2+} , β -Arr1 and β -Arr2 assays). This is so because equation 4 is only valid in cases where the orthosteric agonist has high efficacy ($\tau \gg 1$) such that K_A is $\gg [A]$.

Statistics. All data are represented as mean \pm SEM and were compared using ANOVA followed by Dunnett's test. Repeated measures analysis of variance was used to assess the statistical significance between time courses. The null hypothesis was rejected at $P < 0.05$.

Results

Small molecules ligands and peptides differentially couple the GLP-1R to cellular effectors

The ability of a GPCR to couple to multiple intracellular signalling components is a requirement for stimulus bias. Like most GPCRs, the GLP-1R couples to different classes of heterotrimeric G proteins, including $G\alpha_s$, $G\alpha_q$ and $G\alpha_i$, as well as various other signalling and regulatory proteins such as the β -arrestins (β -Arrests). In this study, the selective GLP-1R small molecules, BETP (Sloop et al., 2010), Compound 2 (Knudsen et al., 2007), TT15 (Rao, 2009), Boc5 (Chen et al., 2007) and a modified GLP-1 analogue (BMS21) (Mapelli et al., 2009) (Figure 1) were assessed for their ability to activate various intracellular signalling pathways. These included cAMP (as a surrogate of canonical $G\alpha_s$ coupling), intracellular Ca^{2+} mobilisation (as a measure of $G\alpha_q$, and to some extent $G\alpha_i$ coupling), pERK1/2 (as a downstream measure of various convergent pathways (G protein and non-G protein-mediated)), and recruitment of the regulatory proteins β -Arr1 and β -Arr2.

GLP-1(7-36)NH₂ can activate all five of these signalling/regulatory pathways in the ChoFlpIn GLP-1R cell line selected for this study, however none of the small molecules or the 11mer peptide (BMS21) tested were able to fully mimic the actions of the native peptide ligand (Figure 2, Table 1). BMS21 had a much lower potency than GLP-1(7-36)NH₂, however this ligand displayed higher efficacy for cAMP signalling with an increased E_{max} (Figure 2, Table 1). Interestingly, this small peptide displayed a similar potency in pERK1/2 and calcium mobilisation assays as in the cAMP assay, however, in these instances the observed E_{max} was dramatically lower than that of GLP-1(7-36)NH₂. In addition, BMS21 was unable to recruit β -Arrests within the tested concentration range (Figure 2, Table 1) suggesting that although this peptide is similar to the N terminal portion of the native ligand, this in itself is insufficient to mimic the functions of full length GLP-1(7-36)NH₂.

In agreement with previous studies, the non-peptidic compound, Boc5 was able to increase cAMP with a lower potency and efficacy than GLP-1(7-36)NH₂ and BMS21 (Figure 2A, Table 1). Boc5 also had similar efficacy in pERK1/2 and intracellular calcium mobilisation assays. No β -Arr recruitment could be detected for this ligand. TT15 displayed a similar potency but a marginally higher E_{max} for cAMP signalling compared to Boc5, however it displayed a weaker pERK1/2 response and no intracellular Ca^{2+} mobilisation was detectable (Figure 2, Table 1). Unfortunately, this ligand non-specifically interfered with BRET assay for β -Arr recruitment and therefore characterisation of TT15 for β -Arr recruitment could not

be performed. Compound 2 and BETP are low potency agonists for cAMP accumulation with BETP displaying weak partial agonism and Compound 2 strong partial agonism. Both compounds also displayed weak partial agonism in pERK1/2, however in the case of BETP this was barely detectable within the concentration range assessed. Compound 2 displayed no detectable intracellular calcium response, however BETP was an agonist for this pathway with an EC₅₀ similar to that observed for its cAMP response, and with an E_{max} of 42 ± 10 % of that of GLP-1(7-36)NH₂. However, both ligands were weak agonists for β-Arr1 and β-Arr2 recruitment with E_{max} estimates of 30-40 % of the response of GLP-1(7-36)NH₂ (Figure 2, Table 1).

These effects on ligand bias can be readily observed in bias plots, which display the response observed to equimolar concentrations of ligand for one pathway relative to another (Figure 3). More importantly, this relative bias can be quantified by calculation of bias factors to compare relative bias to the reference ligand, in this case the primary endogenous ligand GLP-1(7-36)NH₂ (Table 2). It is apparent for all of the small molecule ligands that the GLP-1R shows less preference for coupling to cAMP over other pathways in comparison to when activated by GLP-1(7-36)NH₂. However some ligands heavily change the relative bias. The most dramatic changes in bias are observed with activation by BETP, whereby signalling is biased towards calcium mobilisation and β-Arr1 and -2 recruitment over cAMP and pERK1/2 compared to the reference agonist (Figure 3B-E, 3H, 3J and Table 2). However, little change in the relative bias between calcium and arrestin recruitment was observed (Figure 3F, Table 2). In contrast BMS21 biases the receptor towards pERK1/2 and cAMP over arrestin recruitment and calcium mobilisation relative to GLP-1(7-36)NH₂ (Figure 3C-E, Table 2). In addition, compared to GLP-1(7-36)NH₂, Compound 2 biases the receptor conformations towards β-arrestin-1 and -2 recruitment relative to calcium (where no response was observed) and cAMP (Figure 3F, 3G and Table 2).

BETP and Compound 2 selectively modulate the affinity of agonists at the GLP-1R

In agreement with our previous study, Compound 2 displayed probe dependence in that it caused a concentration-dependent increase in affinity of oxyntomodulin, but not of GLP-1(7-36)NH₂, exendin-4 or GLP-1(1-36)NH₂. BETP also displayed the same probe dependence with potentiation of oxyntomodulin affinity and no effect on the other three peptides (Supplementary figure 2). The other small molecules did not alter the competition binding profile of ¹²⁵I-exendin(9-39) in the presence of any peptide ligand tested.

BETP and Compound 2 differentially alter peptide-mediated GLP-1R signalling bias

Analysis of the interaction between BETP and orthosteric peptide ligands with the allosteric operational model revealed BETP differentially modulated GLP-1R agonist intrinsic efficacy in a ligand and pathway-dependent manner. (Figures 4-7, Table 3). Combined affinity-efficacy ($\alpha\beta$) estimates for cAMP were consistent with affinity cooperativity estimates from the binding studies (Figure 4, supplementary figure 2, Table 3). Thus, exendin-4, GLP-1(7-36)NH₂ and GLP-1(1-36)NH₂ displayed neutral cooperativity for both binding and cAMP accumulation, whereas BETP potentiated oxyntomodulin affinity and cAMP responses (Supplementary figure 2, Figure 4). In contrast, BETP showed significant negative cooperativity with exendin-4, GLP-1(7-36)NH₂ and GLP-1(1-36)NH₂ for coupling to pERK1/2 and neutral/weak negative cooperativity with oxyntomodulin for this pathway. In intracellular Ca²⁺ mobilisation assays, BETP displayed positive cooperativity with exendin-4 and to a lesser extent GLP-1(7-36)NH₂, however neutral cooperativity with oxyntomodulin was observed (Figure 6). Assessment of β -Arr recruitment revealed neutral cooperativity between BETP and exendin-4 for both β -Arr1 and β -Arr2 and neutral cooperativity for GLP-1(7-36)NH₂ in recruiting β -Arr1 (Figure 7, Table 3). However, weak potentiation of β -Arr2 and of both β -Arr1 and β -Arr2 recruitment was observed for GLP-1(7-36)NH₂ and oxyntomodulin respectively in the presence of BETP (Figure 7, Table 3). These data indicate that BETP can engender stimulus bias at the level of the signalling pathway in a ligand-dependent manner.

Functional interaction assays for cAMP accumulation and intracellular Ca²⁺ mobilisation between each peptide ligand and Compound 2 confirmed previous findings (Koole et al., 2010); Compound 2 potentiated oxyntomodulin-induced cAMP responses but not intracellular calcium mobilisation (supplementary figures 3-4). In contrast, neutral cooperativity was observed between Compound 2 and the other three peptides in both pathways. Interaction assays for the pERK1/2 experiments included higher concentrations of Compound 2 than previously published, which revealed significant negative cooperativity of Compound 2 on exendin-4-mediated pERK1/2 responses. A similar trend was observed for both the full length and truncated GLP-1 peptides (and to a lesser extent oxyntomodulin), although this negative cooperativity did not reach statistical significance. In contrast, Compound 2 displayed positive cooperativity with exendin-4, GLP-1(7-36)NH₂ and

oxyntomodulin for recruitment of both β -Arr1 and β -Arr2. The estimated cooperativity factors ($\alpha\beta$) revealed that this potentiation was greater for GLP-1(7-36)NH₂ and oxyntomodulin, than that of exendin-4 (Figure 8). Like BETP, Compound 2 can also generate stimulus bias in a probe-dependent manner; however it is important to note that these two allosteric ligands engender significantly different signalling profiles that only manifest when multiple signalling pathways are explored.

GLP-1(1-36)NH₂ did not display agonism in either intracellular Ca²⁺ mobilisation assays or in recruitment of β -Arrests either in the presence or absence of either BETP or Compound 2.

In contrast to BETP and Compound 2, the small molecules TT15, Boc5 and the BMS21 peptide did not modulate any signalling pathway mediated by any of the GLP-1 peptide agonists (supplementary figures 6-8). These compounds at high concentrations (particularly evident with BMS21) have characteristics consistent with a competitive mode of action with GLP-1 and GLP-1 related peptide agonists, which suggests these small ligands may share at least a partially overlapping binding site with the orthosteric pocket.

BETP and Compound 2 can potentiate responses to BMS21, TT15 and Boc5.

Consistent with the evidence above indicating at least a partial overlap in binding interactions formed by TT15 and BMS21 with orthosteric ligands, these two ligands when tested for interaction with each other in a cAMP assay displayed behaviour consistent with a competitive interaction (supplementary figure 9). In addition, BETP and Compound 2 strongly potentiated cAMP responses mediated by both TT15 and the small peptide, BMS21 (Figure 9, Table 4). Interestingly, BETP also potentiated Boc5-mediated cAMP responses (Figure 9, Table 4), however only weak modulation was observed using Compound 2 (Figure 9, Table 4). This is particularly interesting as Boc5, when interacted in a cAMP assay with either TT15 or BMS, had a profile consistent with competitive behaviour between the two ligands (supplementary figure 9). This indicates that although both ligands may bind in a site partially overlapping the orthosteric site, the cooperativity between the site of Compound 2 binding and Boc5 is different to that of TT15 and BMS21. In addition, the differential degrees of cooperativity induced by the two structurally distinct modulators BETP and Compound 2 indicate that these two compounds interact differentially with the GLP-1R.

Discussion

The GLP-1R is a major therapeutic target for the treatment of type 2 diabetes, however, despite the success of natural or modified GLP-1R binding peptides for clinical treatment, low molecular weight, orally active compounds are still pursued as the preferred therapeutic approach. Traditionally, these types of molecules were designed to mimic the properties of the natural ligand by targeting the orthosteric site and this approach has been successful for many GPCR targets (Black, 1989). However, there are many cases where this has been unsuccessful, in particular for non-family A GPCRs.

Orthosteric peptide ligands for family B GPCRs bind predominantly to the large N-terminal domain prior to initiating receptor activation (Hoare, 2005). This is mechanistically different from many family A GPCRs whose ligands primarily make contact within the transmembrane domain. Due to the size of peptide ligands and their mechanism of receptor activation, the discovery of surrogate small molecule agonists that mimic these actions has been difficult. However, several groups have recently reported small molecule non-peptide and smaller peptide fragments that act as GLP-1R agonists or positive allosteric modulators. In this study we have revealed significant signalling bias induced by these compounds when compared to the predominant endogenous peptide, indicating that small ligands may not be able to fully mimic the actions of larger peptide hormones. In addition, we show that allosteric modulation is complex, with pathway-dependent modulation of receptor response that is determined by the combination of orthosteric ligand and allosteric ligand used. This emphasises the need for broad elucidation of mechanism of action when developing allosteric compounds.

Activation by peptide ligands predominantly couples the GLP-1R to G_{α_s} -proteins leading to an increase in cAMP. This is the best studied pathway of the GLP-1R and is crucial for enhancing glucose-dependent insulin secretion (Baggio and Drucker, 2007). However, like many GPCRs, the GLP-1R elicits signals via diverse pathways, including iCa^{2+} mobilisation and pERK1/2, in addition to coupling to regulatory proteins such as β -Arres that can activate other effectors (Montrose-Rafizadeh et al., 1999; Sonoda et al., 2008). Each of these pathways has been linked to physiological effects of GLP-1. iCa^{2+} mobilisation can significantly modulate the magnitude of insulin secretion and β -Arr1 also has a role in insulin secretion, although the molecular mechanism of this regulation is poorly understood. Sustained effects on gene transcription and the preservation of β cell mass involve multiple

signalling pathways; both cAMP-dependent and independent, the later include activation of mitogen activated kinases, such as ERK1/2. It is clear that the physiological response downstream of GLP-1R activation is a composite of the interplay of various signalling pathways, but even for those that have been identified, the extent and magnitude to which these effectors contribute to the physiological signalling profile and the ideal combination of these that lead to a therapeutically beneficial output has yet to be established.

Evaluation of signalling across five pathways (cAMP, pERK1/2, iCa^{2+} mobilisation, β -Arr1 and β -Arr2 recruitment) demonstrated that, in comparison to the reference ligand (GLP-1(7-36)NH₂), all of the small ligands, with the exception of BETP, coupled most strongly to cAMP production. In addition, for BMS21, TT15 and Boc5, the relative order of efficacy for the five pathways was similar to GLP-1(7-36)NH₂ (Figure 1, Table1). Despite this, each of the ligands showed elements of signal bias, with all three having less preference for cAMP relative to pERK1/2, but no significant change when comparing the preference between all other pathways (Table 2). However, Compound 2 displayed significant signal bias with less preference for cAMP signalling relative to iCa^{2+} , β -Arr1 or β -Arr2. Interestingly BETP displayed a very different profile to GLP-1(7-36)NH₂, as this compound heavily biased GLP-1R signalling to β -Arr1, β -Arr2 and iCa^{2+} mobilisation relative to cAMP and pERK1/2. The response was also biased towards β -Arr1 recruitment and iCa^{2+} mobilisation over β -Arr2 (Table 2). The ability of individual ligands to differentially activate the GLP-1R to produce distinct functional profiles may provide a unique opportunity in drug development, with the potential to sculpt receptor signalling to target physiologically important responses and exclude those that do not provide beneficial outputs.

This concept also extends to allosteric modulation of orthosteric ligand responses. In addition to small molecules displaying differential intrinsic efficacy profiles, if they bind allosterically, they can also differentially modulate peptide (both endogenous and exogenous) responses in a pathway-specific manner. Therefore, determining the modulatory profile of small molecule ligands in numerous functional outputs and using multiple orthosteric ligands is important, especially when the endogenous systems involve the interplay of many natural ligands and several signalling pathways to elicit physiological consequences. Compound 2 engendered significant bias in the response mediated by oxyntomodulin with selective enhancement of cAMP, β -Arr1 and β Arr2, however for GLP-1(7-36)NH₂, only β -Arr responses were enhanced. BETP also engendered significant stimulus bias in a probe-dependent manner, with selective enhancement of oxyntomodulin-mediated cAMP responses

and to a smaller extent β -Arr-1 and-2, but only iCa^{2+} and β -Arr2 responses were weakly enhanced when GLP-1(7-36)NH₂ was co-bound, while a strong negative effect on pERK1/2 was observed. When considering the clinically used exendin-4, the bias was again different; in this case only iCa^{2+} mobilisation was significantly enhanced, with negative cooperativity seen for pERK1/2. This revealed that GLP-1R conformations induced by the co-binding of an allosteric modulator and orthosteric ligand can vastly alter the combined signalling profile of the receptor such that no two combinations of allosteric-orthosteric ligand pair were able to produce the same profile of behaviour. From these studies, it is unclear whether Compound 2 and BETP share a common binding pocket, and further elucidation to identify their binding site(s) will be required. However, even if they do occupy the same pocket, the specific interactions formed between these compounds and the receptor is clearly different as they induce very distinct bias in their efficacy and modulatory properties.

This type of behaviour, where ligands can alter one pathway while having very different effect on another pathway and differential probe-dependent effects at both acute and regulatory signalling pathways, may provide a therapeutic advantage by allowing fine-tuning of receptor response. However, this also presents a significant challenge, as currently it is not clear what the key pathway/combination of pathways that need to be manipulated to provide an ideal therapeutic response will be. Understanding the activity profiles of small ligands may be key for drug discovery programs. These types of compounds that display differential efficacy and modulatory profiles provide us with tools that could potentially be used in an *in vivo/ex vivo* setting to explore the physiological consequences of biased signalling. Further research is required to fully understand these concepts and ascertain the preferred signalling profile for new and better therapeutics.

The final part of this study identified that Compound 2 and BETP were able to strongly modulate cAMP responses of BMS21 and TT15 at the GLP-1R. Boc5 could also be potentiated but to a lesser extent. Data from our interaction assays also suggest that these compounds behave in a competitive manner with peptide ligands and each other. BMS21 was designed to mimic the N-terminal region of GLP-1, which is proposed to bind to the top of the transmembrane bundle and ECL regions of the receptor. It is also possible that TT15 may bind in a similar region. Boc5 has also been proposed to bind in the extracellular regions of the receptor, however its binding site may be distinct to that of BMS and TT15 as weaker cooperativity was observed with BETP and Compound 2. These observations could also represent an opportunity to aid in drug optimisation. For example, ligands like BMS21, TT15

and Boc5 are less biased agonists than Compound 2 and BETP, and if mimicking the actions of GLP-1(7-36)NH₂ rather than altering the bias of the natural hormone was identified as the best therapeutic approach, then elucidation of the binding sites for these ligands could aid in development of higher affinity drug-like molecules that bind to the same binding pocket. Alternatively, all small ligands identified to date display weak affinity for the GLP-1R that could arguably be due to the limited number of contacts they can form with the receptor (compared to peptide ligands). The ability of one small molecule to enhance the signalling induced by another (and vice versa) may indicate some therapeutic potential for small molecule therapies to be used in combination.

In conclusion, we have demonstrated that small molecule ligands induce biased signalling at the GLP-1R and also bias in the signalling profile of orthosteric ligands. Further work is required to delineate the extent to which such bias exists in a native cellular environment and the *in vivo* consequences. In recent years, the pace of identifying small molecule GLP-1R ligands has increased and this should aid in these types of studies that may lead to the discovery and development of compounds with the potential to sculpt therapeutics that show greater selectivity and improved therapeutic outcomes.

Acknowledgements

We thank Dan Kohlman, Mark Tebbe, Mike Coghlan, and Jorge Alsina-Fernandez for their technical assistance and support.

Authorship Contributions

Participated in research design: Wootten D, Willard FS, Sloop KW, Christopoulos A,

Sexton PM

Conducted experiments: Wootten D, Savage EE

Contributed new reagents or analytic tools: Willard FS, Bueno AB, Sloop KW

Performed data analysis: Wootten D, Savage EE

Wrote or contributed to the writing of the manuscript: Wootten D, Willard FS, Bueno AB

Sloop KW, Christopoulos A, Sexton PM

References

- Aurelio L, Valant C, Flynn BL, Sexton PM, Christopoulos A and Scammells PJ (2009) Allosteric modulators of the adenosine A1 receptor: synthesis and pharmacological evaluation of 4-substituted 2-amino-3-benzoylthiophenes. *J Med Chem* **52**(14):4543-4547.
- Avlani VA, McLoughlin DJ, Sexton PM and Christopoulos A (2008) The impact of orthosteric radioligand depletion on the quantification of allosteric modulator interactions. *J Pharmacol Exp Ther* **325**(3):927-934.
- Baggio LL and Drucker DJ (2007) Biology of incretins: GLP-1 and GIP. *Gastroenterology* **132**(6):2131-2157.
- Black J (1989) Drugs from emasculated hormones: the principle of syntopic antagonism. *Science* **245**(4917):486-493.
- Black JW and Leff P (1983) Operational models of pharmacological agonism. *Proc R Soc Lond B Biol Sci* **220**(1219):141-162.
- Buteau J, Foisy S, Joly E and Prentki M (2003) Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor. *Diabetes* **52**(1):124-132.
- Chen D, Liao J, Li N, Zhou C, Liu Q, Wang G, Zhang R, Zhang S, Lin L, Chen K, Xie X, Nan F, Young AA and Wang MW (2007) A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice. *Proc Natl Acad Sci U S A* **104**(3):943-948.
- DeFronzo RA (1992) Pathogenesis of type 2 (non-insulin dependent) diabetes mellitus: a balanced overview. *Diabetologia* **35**(4):389-397.
- Drucker DJ and Nauck MA (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. *Lancet* **368**(9548):1696-1705.
- Drucker DJ, Philippe J, Mojsov S, Chick WL and Habener JF (1987) Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. *Proc Natl Acad Sci U S A* **84**(10):3434-3438.
- Evans BA, Broxton N, Merlin J, Sato M, Hutchinson DS, Christopoulos A and Summers RJ (2011) Quantification of functional selectivity at the human alpha(1A)-adrenoceptor. *Mol Pharmacol* **79**(2):298-307.
- Hoare SR (2005) Mechanisms of peptide and nonpeptide ligand binding to Class B G-protein-coupled receptors. *Drug Discov Today* **10**(6):417-427.
- Holz GGt, Kuhlreiber WM and Habener JF (1993) Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37). *Nature* **361**(6410):362-365.
- Kenakin T (2011) Functional selectivity and biased receptor signaling. *J Pharmacol Exp Ther* **336**(2):296-302.
- Kenakin T, Watson C, Muniz-Medina V, Christopoulos A and Novick S (2012) A simple method for quantifying functional selectivity and agonist bias. *ACS Chem Neurosci* **3**(3):193-203.
- Knudsen LB, Kiel D, Teng M, Behrens C, Bhumralkar D, Kodra JT, Holst JJ, Jeppesen CB, Johnson MD, de Jong JC, Jorgensen AS, Kercher T, Kostrowicki J, Madsen P, Olesen PH, Petersen JS, Poulsen F, Sidelmann UG, Sturis J, Truesdale L, May J and Lau J (2007) Small-molecule agonists for the glucagon-like peptide 1 receptor. *Proc Natl Acad Sci U S A* **104**(3):937-942.
- Koole C, Wootten D, Simms J, Valant C, Miller LJ, Christopoulos A and Sexton PM (2011) Polymorphism and ligand dependent changes in human glucagon-like peptide-1

- receptor (GLP-1R) function: allosteric rescue of loss of function mutation. *Mol Pharmacol* **80**(3):486-497.
- Koole C, Wootten D, Simms J, Valant C, Sridhar R, Woodman OL, Miller LJ, Summers RJ, Christopoulos A and Sexton PM (2010) Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: implications for drug screening. *Mol Pharmacol* **78**(3):456-465.
- Leach K, Sexton PM and Christopoulos A (2007) Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology. *Trends Pharmacol Sci* **28**(8):382-389.
- Mapelli C, Natarajan SI, Meyer JP, Bastos MM, Bernatowicz MS, Lee VG, Pluscec J, Riexinger DJ, Sieber-McMaster ES, Constantine KL, Smith-Monroy CA, Golla R, Ma Z, Longhi DA, Shi D, Xin L, Taylor JR, Koplowitz B, Chi CL, Khanna A, Robinson GW, Seethala R, Antal-Zimanyi IA, Stoffel RH, Han S, Whaley JM, Huang CS, Krupinski J and Ewing WR (2009) Eleven amino acid glucagon-like peptide-1 receptor agonists with antidiabetic activity. *J Med Chem* **52**(23):7788-7799.
- May LT, Avlani VA, Langmead CJ, Herdon HJ, Wood MD, Sexton PM and Christopoulos A (2007) Structure-function studies of allosteric agonism at M2 muscarinic acetylcholine receptors. *Mol Pharmacol* **72**(2):463-476.
- Montrose-Rafizadeh C, Avdonin P, Garant MJ, Rodgers BD, Kole S, Yang H, Levine MA, Schwindinger W and Bernier M (1999) Pancreatic glucagon-like peptide-1 receptor couples to multiple G proteins and activates mitogen-activated protein kinase pathways in Chinese hamster ovary cells. *Endocrinology* **140**(3):1132-1140.
- Park S, Dong X, Fisher TL, Dunn S, Omer AK, Weir G and White MF (2006) Exendin-4 uses Irs2 signaling to mediate pancreatic beta cell growth and function. *J Biol Chem* **281**(2):1159-1168.
- Quoyer J, Longuet C, Broca C, Linck N, Costes S, Varin E, Bockaert J, Bertrand G and Dalle S (2010) GLP-1 mediates antiapoptotic effect by phosphorylating Bad through a beta-arrestin 1-mediated ERK1/2 activation in pancreatic beta-cells. *J Biol Chem* **285**(3):1989-2002.
- Rao M (2009) Ligands For The Glp-1 Receptor And Methods For Discovery Thereof, in (I.P. Application E, PCT/US2009/039905 ed), TransTech Pharma.
- Sloop KW, Willard FS, Brenner MB, Ficorilli J, Valasek K, Showalter AD, Farb TB, Cao JX, Cox AL, Michael MD, Gutierrez Sanfeliciano SM, Tebbe MJ and Coghlan MJ (2010) Novel small molecule glucagon-like peptide-1 receptor agonist stimulates insulin secretion in rodents and from human islets. *Diabetes* **59**(12):3099-3107.
- Sonoda N, Imamura T, Yoshizaki T, Babendure JL, Lu JC and Olefsky JM (2008) Beta-Arrestin-1 mediates glucagon-like peptide-1 signaling to insulin secretion in cultured pancreatic beta cells. *Proc Natl Acad Sci U S A* **105**(18):6614-6619.
- Werry TD, Gregory KJ, Sexton PM and Christopoulos A (2005) Characterization of serotonin 5-HT_{2C} receptor signaling to extracellular signal-regulated kinases 1 and 2. *J Neurochem* **93**(6):1603-1615.
- Willard FS, Bueno AB and Sloop KW (2012a) Small molecule drug discovery at the glucagon-like peptide-1 receptor. *Exp Diabetes Res* 2012:709893.
- Willard FS, Wootten D, Showalter AD, Savage EE, Ficorilli J, Farb TB, Bokvist K, Alsina-Fernandez J, Furness SG, Christopoulos A, Sexton P and Sloop KW (2012b) Small Molecule Allosteric Modulation of the Glucagon-Like Peptide-1 Receptor Enhances the Insulinotropic Effect of Oxyntomodulin. *Mol Pharmacol* **Dec;82**(6):1066-1073.

Footnotes

This work was funded by National Health and Medical Research Council project grant [1002180] and National Health and Medical Research Council program grant [519461]. Panel C in figures 4, 5, 6 and 7 are reproduced from figure 4 (panels A-D) in Willard et al (2012b).

Figure Legends

Figure 1. Small molecule ligand structures.

Structures of small molecule ligands used in this study.

Figure 2. Signalling profiles of GLP-1R ligands.

Dose response curves for cAMP accumulation (A), pERK1/2 (B), iCa^{2+} mobilisation (C), β -Arr1 recruitment (D) and β -Arr2 (E) recruitment for GLP-1(7-36)NH₂, BMS21, Boc5, TT15, BETP and Compound 2. Data are normalised to the response elicited by GLP-1(7-36)NH₂ and analysed using a three parameter logistic equation. All values are means \pm S.E.M of three to four independent experiments, conducted in duplicate.

Figure 3. Synthetic ligands display stimulus bias relative to the endogenous ligand GLP-1(7-36)NH₂.

Bias plots of cAMP vs pERK1/2 (A), cAMP vs iCa^{2+} mobilisation (B), cAMP vs β -Arr1 (C), cAMP vs β -Arr2 (D), iCa^{2+} vs pERK1/2 (E), iCa^{2+} vs β -Arr1 (F), iCa^{2+} vs β -Arr2 (G), β -Arr1 vs pERK1/2 (H), β -Arr1 vs β -Arr2 (I), β -Arr2 vs pERK1/2 (J). Data for each ligand in each pathway are normalised to the maximal response elicited by GLP-1(7-36)NH₂, and analysed with a three-parameter logistic equation, with 150 points defining the curve.

Figure 4. BETP displays positive allosteric effects on GLP-1R-mediated cAMP accumulation in an agonist-dependent manner.

Concentration response curves were generated for exendin-4 (A), GLP-1(7-36)NH₂ (B), Oxyntomodulin (C) or GLP-1(1-36)NH₂ (D) in the absence and presence of increasing concentrations of BETP in FlpInCHO cells stably expressing the human GLP-1R. The curves represent the best global fit of an operational model of allosterism (equation 4). All values are mean \pm SEM of three to four independent experiments performed in duplicate.

Figure 5. BETP displays negative allosteric effects on GLP-1R-mediated pERK1/2 by peptide ligands .

Concentration response curves were generated for exendin-4 (A), GLP-1(7-36)NH₂ (B), Oxyntomodulin (C) or GLP-1(1-36)NH₂ (D) in the absence and presence of increasing concentrations of BETP in FlpInCHO cells stably expressing the human GLP-1R. The curves represent the best global fit of an operational model of allosterism (equation 5). All values are mean \pm SEM of three to four independent experiments performed in duplicate.

Figure 6. BETP positively modulates GLP-1R-mediated iCa^{2+} mobilisation by peptide ligands.

Concentration response curves were generated for exendin-4 (A), GLP-1(7-36)NH₂ (B) or Oxyntomodulin (C) in the absence and presence of increasing concentrations of BETP in FlpInCHO cells stably expressing the human GLP-1R. The curves represent the best global fit of an operational model of allosterism (equation 5). All values are mean \pm SEM of three to four independent experiments performed in duplicate.

Figure 7. BETP does not significantly alter GLP-1R-mediated recruitment of β -arrestins by peptide ligands.

Concentration response curves were generated for exendin-4 (A, D), GLP-1(7-36)NH₂ (B, E) or Oxyntomodulin (C, F) in the absence and presence of increasing concentrations of BETP for β -Arr1 (A-C) and β -Arr2 (D-F) recruitment. The curves represent the best global fit of an

operational model of allosterism (equation 5). All values are mean \pm SEM of four to five independent experiments performed in duplicate.

Figure 8. Compound 2 potentiates GLP-1R-mediated recruitment of β -arrestins by peptide ligands.

Concentration response curves were generated for exendin-4 (A, D), GLP-1(7-36)NH₂ (B, E) or Oxymodulin (C, F) in the absence and presence of increasing concentrations of Compound 2 for β -Arr1 (A-C) and β -Arr2 (D-F) recruitment. The curves represent the best global fit of an operational model of allosterism (equation 5). All values are mean \pm SEM of four to five independent experiments performed in duplicate.

Figure 9. Compound 2 and BETP potentiate GLP-1R-mediated cAMP accumulation by BMS21, Boc5 and TT15.

Concentration response curves were generated for BMS21 (A, B), Boc5 (C, D) or TT15 (E, F) in the absence and presence of increasing concentrations of either Compound 2 (A, C, E) or BETP (B, D, F) in FlpInCHO cells stably expressing the human GLP-1R. The curves represent the best global fit of an operational model of allosterism (equation 5). All values are mean \pm SEM of three independent experiments performed in duplicate.

Table 1

Differential effects of peptide/small molecule agonists of the human GLP-1R in cAMP accumulation, $i\text{Ca}^{2+}$ mobilisation, pERK1/2, β -arrestin1 and β -arrestin2 recruitment in FlpInCHO cells stably expressing the human GLP-1R. pEC50 values are the negative logarithm of the concentration of agonist that produces half the maximal response. Emax represents the maximal response normalized to that of GLP-1(7–36)NH₂. All values are mean S.E.M. of three to five independent experiments, conducted in duplicate. ND indicates data unable to be detected due to interference of the ligand with the assay and NR indicated no response detectable within the concentration range tested.

Signalling Pathway	Ligand						
	GLP-1(7-36)NH ₂	BMS21	Boc5	TT15	BETP	Compound 2	
cAMP	pEC ₅₀	10.4 ± 0.1	6.7 ± 0.6	6.7 ± 0.2	6.5 ± 0.2	5.2 ± 0.2	5.6 ± 0.1
	Emax	100 ± 2	132 ± 6	30 ± 2	46 ± 3	17 ± 2	81 ± 4
pERK1/2	pEC ₅₀	7.9 ± 0.1	6.8 ± 0.1	6.5 ± 0.1	6.7 ± 0.3	NR	6.2 ± 0.1
	Emax	100 ± 5	46 ± 2	19 ± 1	12 ±	NR	18 ± 1
$i\text{Ca}^{2+}$	pEC ₅₀	7.9 ± 0.1	7.0 ± 0.3	6.0 ± 0.3	NR	5 ± 0.3	NR
	Emax	100 ± 5	17 ± 3	22 ± 2	NR	42 ± 10	NR
β -Arr1	pEC ₅₀	7.7 ± 0.1	NR	NR	ND	5.0 ± 0.2	5.0 ± 0.2
	Emax	100 ± 6	NR	NR	ND	40 ± 7	30 ± 5
β -Arr2	pEC ₅₀	7.4 ± 0.1	NR	NR	ND	5.0 ± 0.3	4.8 ± 0.2
	Emax	100 ± 5	NR	NR	ND	63 ± 15	51 ± 0.2

Table 2. Stimulus bias exhibited by ligands relative to the reference agonist GLP-1(7-36)NH₂

Data were analysed using an operational model of agonism as defined in equation 4 to estimate $\log\tau_0/K_A$ ratios. Changes in $\log\tau_0/K_A$ ratios were calculated to provide a measure of the degree of stimulus bias exhibited between different signalling pathways relative to that of the reference agonist (GLP-1(7-36)NH₂). Values are expressed as means \pm S.E.M of three to five independent experiments, conducted in duplicate. Data were analysed with one-way analysis of variance and Dunnett's post test (* $p < 0.05$). ND indicates data unable to be experimentally defined.

Pathway 1:Pathway2	Ligand						
	GLP-1(7-36)NH ₂	BMS21	Boc5	TT15	BETP	Compound 2	
pERK1/2: cAMP	0 \pm 0.11 (1)	0.83 \pm 0.34 (6.7)	1.77 \pm 0.49* (59)	1.45 \pm 0.55 (28)	1.09 \pm 0.60 (12)	1.05 \pm 0.43 (11)	
	iCa ²⁺	0 \pm 0.10 (1)	0.28 \pm 0.36 (1.9)	-0.22 \pm 0.56 (0.6)	ND	-1.23 \pm 0.44 (0.06)	ND
	β -Arr1	0 \pm 0.09 (1)	ND	ND	ND	-1.39 \pm 0.46 (0.04)*	0.22 \pm 0.46 (1.7)
	β -Arr2	0 \pm 0.11 (1)	ND	ND	ND	-1.97 \pm 0.46 (0.01)*	-0.08 \pm 0.44 (0.83)
iCa: cAMP	0 \pm 0.14 (1)	0.60 \pm 0.37 (3.9)	0.52 \pm 0.28 (3.3)	ND	1.74 \pm 0.42 (55)*	ND	
	pERK1/2	0 \pm 0.10 (1)	-0.28 \pm 0.36 (0.53)	0.22 \pm 0.56 (1.6)	ND	1.23 \pm 0.44 (20)	ND
	β -Arr1	0 \pm 0.08 (1)	ND	ND	ND	-0.16 \pm 0.16 (0.70)	ND
	β -Arr2	0 \pm 0.14 (1)	ND	ND	ND	-1.22 \pm 0.16 (0.06)*	ND
β -Arr1: cAMP	0 \pm 0.09 (1)	ND	ND	ND	2.38 \pm 0.43 (239)*	1.73 \pm 0.22 (54)*	
	pERK1/2	0 \pm 0.09 (1)	ND	ND	ND	1.39 \pm 0.46 (24)*	-0.22 \pm 0.46 (0.61)
	iCa ²⁺	0 \pm 0.08 (1)	ND	ND	ND	0.16 \pm 0.16 (1.43)	ND
	β -Arr2	0 \pm 0.10 (1)	ND	ND	ND	-0.58 \pm 0.19 (0.26)	-0.3 \pm 0.24 (0.50)
β -Arr2: cAMP	0 \pm 0.11 (1)	ND	ND	ND	2.96 \pm 0.43 (918)*	2.03 \pm 0.17 (108)*	
	pERK1/2	0 \pm 0.11 (1)	ND	ND	ND	1.97 \pm 0.46 (93)*	0.08 \pm 0.44 (1.2)
	iCa ²⁺	0 \pm 0.16 (1)	ND	ND	ND	1.22 \pm 0.16 (17)*	ND
	β -Arr1	0 \pm 0.10 (1)	ND	ND	ND	0.58 \pm 0.19 (3.8)	0.3 \pm 0.24 (2.0)

Table 3. Functional cooperativity estimates for the interaction between BETP or Compound 2 and GLP-1R peptide ligands.

Data derived from analysis of interaction concentration-response curves with an operational model of allosterism as defined in equations 4 and 5. pKb values are the negative logarithms for the functional affinity of the allosteric ligands, $\log \alpha\beta$ represent the composite cooperativity between the allosteric ligand and the orthosteric peptide ligand. Antilogarithms are shown in parentheses. Values represent the mean \pm S.E.M of four to six independent experiments performed in duplicate. Data were analysed with one-way analysis of variance and Dunnett's post test (* $p < 0.05$). NR indicates no response within the tested concentration range in either the presence or absence of the allosteric ligand, therefore a cooperativity factor could not be defined.

Pathway	Allosteric Ligand	pKb	Log $\alpha\beta$ ($\alpha\beta$)			
			Exendin-4	GLP-1(7-36)NH ₂	Oxyntomodulin	GLP-1(1-36)NH ₂
cAMP	BETP	5.01 \pm 0.04	0.45 \pm 0.20 (2.8)	0.31 \pm 0.18 (2.0)	1.21 \pm 0.17 (16)*	0.20 \pm 0.12 (1.6)
	Cpd2	5.43 \pm 0.29	0.24 \pm 0.30 (1.7)	0.22 \pm 0.28 (1.7)	1.48 \pm 0.27 (29)*	0.31 \pm 0.17 (2.0)
pERK1/2	BETP	5.46 \pm 0.29	-0.90 \pm 0.21 (0.13)*	-1.03 \pm 0.23 (0.09)*	-0.44 \pm 0.19 (0.36)	-1.85 \pm 0.88 (0.01)
	Cpd2	5.29 \pm 0.19	-0.77 \pm 0.21 (5.9)	-0.48 \pm 0.17 (0.33)	-0.21 \pm 0.13 (0.62)	-0.44 \pm 0.20 (0.36)
iCa ²⁺	BETP	4.83 \pm 0.16	1.0 \pm 0.26 (10)*	0.58 \pm 0.19 (3.8)	0.23 \pm 0.11 (1.7)	NR
	Cpd2	5.58 \pm 0.38	0.28 \pm 0.15 (1.9)	-0.20 \pm 0.15 (0.63)	0.14 \pm 0.16 (1.4)	NR
β -Arr1	BETP	5.42 \pm 0.17	-0.05 \pm 0.04 (0.89)	-0.01 \pm 0.02 (1.0)	0.40 \pm 0.17 (2.5)	NR
	Cpd2	5.27 \pm 0.18	0.72 \pm 0.18 (5.2)*	1.07 \pm 0.19 (12)*	1.05 \pm 0.14 (11)*	NR
β -Arr2	BETP	5.38 \pm 0.16	0.18 \pm 0.26 (1.5)	0.67 \pm 0.18 (4.7)	0.54 \pm 0.19 (3.5)	NR
	Cpd2	5.30 \pm 0.19	0.69 \pm 0.20 (4.9)*	1.06 \pm 0.13 (11)*	0.99 \pm 0.19 (10)*	NR

Table 4. Functional cooperativity estimates for the interaction between BETP or Compound 2 and Boc5, TT15 or BMS21.

Data derived from analysis of interaction dose-response curves with an operational model of allosterism as defined in equation 4. Log $\alpha\beta$ represent the composite cooperativity between the allosteric ligand and the orthosteric peptide ligand. Antilogarithms are shown in parentheses. Values represent the mean \pm S.E.M of four to six independent experiments performed in duplicate. Data were analysed with Data were analysed with one-way analysis of variance and Dunnett's post test (* $p < 0.05$).

	Log $\alpha\beta$ ($\alpha\beta$)	
	Compound 2	BETP
Boc5	0.84 \pm 0.39 (6.9)*	1.28 \pm 0.44 (19)*
TT15	1.89 \pm 0.41 (78)*	1.66 \pm 0.28 (46)*
BMS21	2.09 \pm 0.35 (123)*	2.75 \pm 0.22 (562)*

Figure 1









Figure 2


A.

cAMP accumulation




B.

pERK1/2




C.

Calcium mobilisation




D.

β-Arr1 recruitment



E.

β-Arr2 recruitment



- GLP-1(7-36)NH₂
- BMS21
- △ Boc5
- ▽ TT15
- ◇ BETP
- Compound 2

loaded from molpharm.aspenjournals.org at ASPET Journals on April 19, 2024

Figure 3






Figure 4.


A.




B.



C.



D.




[BETP] ● 0 □ 10 nM ▲ 0.1 μM ▼ 1 μM ◇ 10 μM ○ 30 μM


Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 19, 2024

Figure 5


A.




B.



C.



D.



[BETP] ● 0 □ 10 nM ▲ 0.1 μM ▼ 1 μM ◇ 10 μM ○ 30 μM

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 19, 2024

Figure 6






Figure 7


A.




B.




C.




D.



E.



F.




[BETP] ● 0 □ 0.1 μM △ 1 μM ▽ 3 μM ◇ 10 μM ○ 30 μM


Downloaded from molpharm.physoc.org at ASPET Journals on April 19, 2024

Figure. 8


A.




B.




C.




D.



E.



F.






[Compound 2] ● 0 □ 0.1 μM △ 1 μM ▽ 3 μM ◇ 10 μM ○ 30 μM




Downloaded from molpharm.physiol.org at ASPET Journals on April 19, 2024

Figure 9

Compound 2



BETP



[Compound 2] or [BETP] ● 0 □ 0.1 μM ◇ 0.3 μM ▽ 1 μM △ 3 μM ○ 10 μM ⬡ 30 μM